Iptacopan is a complement factor B inhibitor targeting the overactive alternative complement pathway in IgA nephropathy.

One drink was the clear winner. Here’s why you should start your day with it.

Using a registry of real-world patients with lupus nephritis, investigators studied trajectories of kidney function decline over a decade.

The Vital Role of Kidneys The kidneys are essential organs in our body, primarily responsible for filtering blood and ...

The relationship between cardiovascular dysfunction and renal impairment is widely recognized as the cardiorenal interaction, ...

Scientists at the Buck Institute for Research on Aging have shown that an orally administered small molecule, ...

Beets are packed with nutrients—but their oxalate content raises questions for people prone to kidney stones. Here’s what ...

Basel, March 29, 2026 – Novartis today announced final two-year results from the Phase III APPLAUSE‑IgAN study of Fabhalta ® (iptacopan) in IgA nephropathy (IgAN). Fabhalta demonstrated a ...

A recent policy change in how patients are assessed for a kidney transplant has helped Black patients get on the list of ...